Pirsue

RSS

pirlimycin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 18/06/2021

Authorisation details

Product details
Name
Pirsue
Agency product number
EMEA/V/C/000054
Active substance
pirlimycin
International non-proprietary name (INN) or common name
pirlimycin
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) codes
QJ51FF90
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
29/01/2001
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

18/06/2021 Pirsue - EMEA/V/C/000054 - IB/0027/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antibacterials for intramammary use

Therapeutic indication

For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings